Evidence map›Paper›PMID 41634744›Full record

ArticleClinical epigenetics2026

Methylation profile characteristics in the H19/IGF2:IG-DMR revealed by long-read sequencing analysis in patients with Beckwith-Wiedemann syndrome having defects in the OCT4/SOX2 binding site.

Hayate Masubuchi, Tatsuki Urakawa, Rika Kosaki, Riki Nishimura, Yasunori Wada, Sumito Dateki, Hideaki Yagasaki, Reiko Kagawa, Yutaka Nishimura, Hidenobu Soejima and 3 more

Abstract read
In one paragraph

Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hayate MasubuchiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 aOkura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Tatsuki UrakawaDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 aOkura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Rika KosakiDivision of Medical Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Riki NishimuraDepartment of Pediatrics, Tokyo University, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yasunori WadaDepartment of Pediatrics, Iwate Medical University, 2-1-1, Idaidori, Yahaba, 028-3695, Japan.
Sumito DatekiDepartment of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.
Hideaki YagasakiDepartment of Pediatrics, University of Yamanashi, 1110, Shimokato, Chuo, 409-3898, Japan.
Reiko KagawaDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3, Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Yutaka NishimuraDepartment of Neonatology, Hiroshima City Hiroshima Citizens Hospital, 7-33 Motomachi, Naka-Ku, Hiroshima, 730-8518, Japan.
Hidenobu SoejimaDepartment of Biomolecular Sciences, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Tsutomu OgataDepartment of Pediatrics, Hamamatsu Medical Center, 328 Tomizuka-Cho, Chuo-Ku, Hamamatsu, 432-8580, Japan.
Maki FukamiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 aOkura, Setagaya-Ku, Tokyo, 157-8535, Japan.
Masayo KagamiDepartment of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 aOkura, Setagaya-Ku, Tokyo, 157-8535, Japan. kagami-ms@ncchd.go.jp.

Funding

Japan Agency for Medical Research and Development 23ek0109672Japan Agency for Medical Research and Development 24ek0109587Japan Society for the Promotion of Science 22K07858 [C]the National Center for Child Health and Development 2022B-5
6 · The paper itself

Abstract

backgroundBeckwith-Wiedemann syndrome (BWS) is an imprinting disorder with characteristic clinical features such as overgrowth and macroglossia. Hypermethylation of the H19/IGF2:IG-differentially methylated region (H19-DMR) is identified in 5% of BWS patients. Although defects in the OCT4/SOX2 binding sites (OBS) on the maternal allele have been reported in patients with hypermethylated H19-DMR, the precise methylation patterns in patients with OBS abnormalities remain elusive. Nanopore long-read sequencing (LRS) obtains sequence reads 10-100 kb long together with single-molecule DNA modifications, such as 5-methylcytosines. Furthermore, LRS can separate reads into haplotypes 1 and 2 based on information from single-nucleotide variants and indels on reads. Here, we conducted LRS to elucidate the abnormal hypermethylation patterns of the H19-DMR in BWS patients with and without OBS abnormalities and evaluate the differences between mothers and their offspring in familial cases with OBS abnormalities.

resultsWe included 14 sporadic patients and four familial patients from two families with BWS showing hypermethylation of the H19-DMR. Amplicon sequencing for the H19-DMR detected OBS abnormalities in four (28.6%) sporadic cases (three point mutations, one 21-bp microdeletion overlapping OBS), an OBS point mutation in family A, and a 2.6 kb deletion involving OBS in family B. Subsequently, we conducted targeted LRS and examined methylation indexes for 247 CpGs in the H19-DMR in three sporadic patients with OBS abnormalities, two sporadic patients without OBS abnormalities, and all familial patients with OBS abnormalities. In patients with point mutations and a 21-bp microdeletion affecting a single base in OBS, CpGs in the H19-DMR had obvious hypermethylation in the vicinity of OBS and mild-to-moderate hypermethylation with increased distance from OBS; however, in patients with deletions including OBS, CpGs had moderate hypermethylation in the entire H19-DMR. In families A and B, methylation levels were higher in offspring than in their mothers.

conclusionBecause 28.6% of sporadic patients had OBS abnormalities, genetic examination for OBS should be considered in BWS patients with hypermethylated H19-DMR. LRS analysis for the H19-DMR revealed differences in methylation patterns between patients with and without OBS abnormalities and the methylation levels of each CpG between mothers and their offspring in families with OBS abnormalities.

Indexed as

Beckwith-Wiedemann SyndromeDNA MethylationInsulin-Like Growth Factor IIOctamer Transcription Factor-3RNA, Long NoncodingSOXB1 Transcription FactorsBinding SitesChildChild, PreschoolFemaleGenomic ImprintingHumansInfantMaleNanopore SequencingSequence Analysis, DNAH19 long non-coding RNAIGF2 protein, humanInsulin-Like Growth Factor IIOctamer Transcription Factor-3POU5F1 protein, humanRNA, Long NoncodingSOX2 protein, humanSOXB1 Transcription FactorsBeckwith-Wiedemann syndromeH19/IGF2:IG-DMRLong-read sequencingMethylation analysisOCT4/SOX2 binding site

Identifiers

PMID41634744
PMCPMC12958509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.